ACST Stock – (NASDAQ: ACST) is actually providing an update on the use
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or maybe the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is actually providing an update on the usage of the “at the market” equity of its providing program.
As previously disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC (collectively, the “Agents”), to carry out a “at the market” equity offering system under which Acasti may issue as well as market from time to time the everyday shares of its having an aggregate offering price of up to seventy five dolars million in the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the last distributions found on January 27, 2021, Acasti issued an aggregate of 20,159,229 common shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 zillion. The ATM Shares were offered at prevailing market costs averaging US$1.0747 a share. No securities had been marketed throughout the facilities of the TSXV or perhaps, to the knowledge of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S-3 (No. 333 239538) as made effective on July seven, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate yucky proceeds raised was paid to the Agents in connection with the services of theirs. As a consequence of the latest ATM sales, Acasti has a total of 200,119,659 common shares issued and great as of March five, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and can supply the Company with more flexibility in its ongoing review process to enjoy as well as evaluate strategic alternatives.
About Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically concentrated on the research, development and commercialization of prescribed drugs using OM3 greasy acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, produced from krill oil. OM3 fatty acids have extensive clinical proof of safety as well as efficacy in lowering triglycerides in patients with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being formulated for patients with serious HTG.
Forward Looking Statements – ACST Stock
Statements in that press release which aren’t statements of current or historical fact constitute “forward-looking information” within the meaning of Canadian securities laws and “forward looking statements” to the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward-looking assertions involve known and unknown risks, uncertainties, along with other unknown elements that might result in the particular results of Acasti to be materially different from historical outcomes and as a result of any future outcomes expressed or perhaps implied by such forward-looking statements. In addition to statements which explicitly describe such risks as well as uncertainties, people are actually urged to consider statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or some other related expressions to be forward-looking and uncertain. Readers are actually cautioned not to place undue reliance on these forward looking statements, which speak only as of the day of this particular press release. Forward-looking claims in this press release include, but are not limited to, info or statements concerning Acasti’s strategy, succeeding operations as well as its review of strategic options.
The forward looking claims found in this specific press release are expressly qualified in their entirety by this alerting statement, the “Special Note Regarding Forward Looking Statements” area contained in Acasti’s latest annual report on Form 10 K and quarterly report on Form 10 Q, which are readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and also on the investor area of Acasti’s site at www.acastipharma.com. Many forward-looking claims in this press release are manufactured as of the day of this particular press release.
ACST Stock – Acasti doesn’t undertake to redesign any such forward-looking statements whether as a direct result of brand new info, future events or otherwise, except as needed by law. The forward-looking assertions contained herein are also subject generally to assumptions and risks and uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities as well as exchange Commission and The Canadian securities commissions, including Acasti’s newest annual report on Form 10 K and quarterly report on Form 10-Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is providing an update on the use